CMPX
Compass TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
CMPX vs peer average
40/100
CMPX vs. peer average (D vs. C)
Grade spread
A 1 · B 2 · C 2 · D 2 · F 3
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
IMRX is the first available peer comparator.
Immuneering is a small-cap clinical oncology biotech where valuation is driven by early pipeline proof points rather than current revenue, making it a closer event-volatility comp than broad biotech indices.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
CMPX
Compass Therapeutics
IMRX
Immuneering
Grade
D
C
Momentum
35
29
Value
41
41
Sentiment
46
85
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Mixed
Grade position vs IMRX
CMPX / IMRX
Grade Position
Below peers
CMPX vs. peer average (D vs. C)
40/100
Momentum
35
CMPXValue
41
CMPXSentiment
46
IMRXRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs CMPX
IMRX is the first peer returned for this comparison set.